Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Snake venom C-type lectin-like proteins (snaclecs) are a major family of non-enzymatic toxins found primarily in the venom of vipers and pit vipers (Clemetson, 2010, Toxicon). Structurally, they belong to the C-type lectin domain superfamily but generally lack the functional calcium-binding residues necessary for carbohydrate recognition, instead evolving to bind protein targets with high specificity (Morita, 2005, Toxicon). These proteins disrupt host hemostasis by binding to platelet receptors such as Glycoprotein Ib (GPIb), Glycoprotein VI (GPVI), and C-type lectin-like receptor 2 (CLEC-2), or to blood coagulation factors like Factor IX and Factor X (Lu et al., 2005, J Thromb Haemost). Such interactions can either induce or inhibit platelet aggregation and the coagulation cascade, leading to clinical complications like venom-induced consumptive coagulopathy and systemic hemorrhage (Eble, 2019, Molecules). In a therapeutic context, snaclecs are the primary targets for neutralization by antivenoms, which consist of antibodies that bind the toxins and prevent their interaction with host proteins. Furthermore, due to their high affinity for vascular receptors, snaclecs serve as valuable research tools and structural templates for the development of novel anticoagulant and antiplatelet drugs (Clemetson, 2010, Toxicon).
Antivenom antibodies bind to the snaclec proteins, preventing their interaction with host platelet receptors and coagulation factors, thereby neutralizing their toxic effects on the hemostatic system.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Snake venom C-type lectin-like protein (Snaclec).